Samuel C, Cornman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther (Heidelb). 2023;13:729–49. https://doi.org/10.1007/s13555-023-00892-5.

Article  PubMed  PubMed Central  Google Scholar 

Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76:736–44. https://doi.org/10.1016/j.jaad.2016.12.005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schwartz DM, Bonelli M, Gadina M, O’Shea JJ. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25–36. https://doi.org/10.1038/nrrheum.2015.167.

Article  CAS  PubMed  Google Scholar 

Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393:2303–11. https://doi.org/10.1016/S0140-6736(19)30419-2.

Article  PubMed  Google Scholar 

Van Der Heijde D, Song I-H, Pangan AL, Deodhar A, Van Den Bosch F, Maksymowych WP, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019;394:2108–17. https://doi.org/10.1016/S0140-6736(19)32534-6.

Article  PubMed  Google Scholar 

Sandborn WJ, Feagan BG, Loftus EV, Peyrin-Biroulet L, Van Assche G, D’Haens G, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease. Gastroenterology. 2020;158:2123-8.e8. https://doi.org/10.1053/j.gastro.2020.01.047.

Article  CAS  PubMed  Google Scholar 

Levy G, Guglielmelli P, Langmuir P, Constantinescu SN. JAK inhibitors and COVID-19. J Immunother Cancer. 2022;10:e002838. https://doi.org/10.1136/jitc-2021-002838.

Article  PubMed  PubMed Central  Google Scholar 

McInnes IB, Anderson JK, Magrey M, Merola JF, Liu Y, Kishimoto M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021;384:1227–39. https://doi.org/10.1056/NEJMoa2022516.

Article  CAS  PubMed  Google Scholar 

Yang F, Lu C, Wang Y, Liu H, Leng X, Zeng X. Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2023;42:1593–605. https://doi.org/10.1007/s10067-023-06529-4.

Article  PubMed  Google Scholar 

Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158:1554-73.e12. https://doi.org/10.1053/j.gastro.2020.01.001.

Article  CAS  PubMed  Google Scholar 

King B, Senna MM, Mesinkovska NA, Lynde C, Zirwas M, Maari C, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024;91:880–8. https://doi.org/10.1016/j.jaad.2024.06.097.

Article  CAS  PubMed  Google Scholar 

King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, et al. Integrated safety analysis of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program. Am J Clin Dermatol. 2024;25:299–314. https://doi.org/10.1007/s40257-024-00846-3.

Article  PubMed  PubMed Central  Google Scholar 

Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin C-Y, et al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24:443–51. https://doi.org/10.1007/s40257-023-00764-w.

Article  PubMed  PubMed Central  Google Scholar 

Paller AS, Ladizinski B, Mendes-Bastos P, Siegfried E, Soong W, Prajapati VH, et al. Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the Measure Up 1, Measure Up 2, and AD Up randomized clinical trials. JAMA Dermatol. 2023;159:526. https://doi.org/10.1001/jamadermatol.2023.0391.

Article  PubMed  PubMed Central  Google Scholar 

Reich K, Teixeira HD, De Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397:2169–81. https://doi.org/10.1016/S0140-6736(21)00589-4.

Article  CAS  PubMed  Google Scholar 

Li C, Li Z, Cao Y, Li L, Li F, Li Y, et al. Tofacitinib for the treatment of nail lesions and palmoplantar pustulosis in synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome. JAMA Dermatol. 2021;157:74. https://doi.org/10.1001/jamadermatol.2020.3095.

Article  PubMed  PubMed Central  Google Scholar 

Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387:1445–55. https://doi.org/10.1056/NEJMoa2118828.

Article  CAS  PubMed  Google Scholar 

Elmariah SB, Smith JS, Merola JF. JAK in the [black] box: a dermatology perspective on systemic JAK inhibitor safety. Am J Clin Dermatol. 2022;23:427–31. https://doi.org/10.1007/s40257-022-00701-3.

Article  PubMed  Google Scholar 

Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156:1333. https://doi.org/10.1001/jamadermatol.2020.3260.

Article  PubMed  PubMed Central  Google Scholar 

Piraccini BM, Cedirian S, Pampaloni F, Rapparini L, Quadrelli F, Bruni F, et al. Effectiveness and safety of baricitinib in severe alopecia areata: 48‐week results. Acad Dermatol Venereol. 2025. https://doi.org/10.1111/jdv.70067.

Article  Google Scholar 

Piraccini BM, Pampaloni F, Cedirian S, Quadrelli F, Bruni F, Rapparini L, et al. Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: a 24-week Italian study. J Eur Acad Dermatol Venereol. 2025;39:1143–51. https://doi.org/10.1111/jdv.20312.

Article  CAS  PubMed  Google Scholar 

Starace M, Pampaloni F, Quadrelli F, Olivoni G, Cedirian S, Rapparini L, et al. Effectiveness of baricitinib on nail alopecia areata: a 48-week single-center retrospective study. Clin Drug Investig. 2026;46(4):447–53. https://doi.org/10.1007/s40261-026-01533-3.

Article  CAS  PubMed  Google Scholar 

Guo L, Feng S, Sun B, Jiang X, Liu Y. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta‐analysis. Acad Dermatol Venereol. 2020;34:192–201. https://doi.org/10.1111/jdv.15937.

Article  CAS  Google Scholar 

Sechi A, Song J, Dell’Antonia M, Heidemeyer K, Piraccini BM, Starace M, et al. Adverse events in patients treated with Jak-inhibitors for alopecia areata: a systematic review. J Eur Acad Dermatol Venereol. 2024. https://doi.org/10.1111/jdv.19090. (Online ahead of print).

Article  PubMed  Google Scholar 

Yoon S, Kim K, Shin K, Kim H-S, Kim B, Kim M-B, et al. The safety of systemic janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2024;38:52–61. https://doi.org/10.1111/jdv.19426.

Article  CAS  PubMed  Google Scholar 

Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396:255–66. https://doi.org/10.1016/S0140-6736(20)30732-7.

Article  CAS  PubMed  Google Scholar 

Rønnstad ATM, Isufi D, Bunick CG, Chovatiya R, Nielsen M-L, Alinaghi F, et al. Real-world evidence of effectiveness and safety of abrocitinib, baricitinib and uadacitinib in atopic dermatitis: a systematic review and meta-analysis. Am J Clin Dermatol. 2025;26(3):411–24. https://doi.org/10.1007/s40257-025-00997-x.

Article  PubMed  Google Scholar